C

    Cassava Sciences Inc (SAVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.38
    +0.00 (+0.00%)

    Market Cap: $114.97M

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(24/34)
    Avg Surprise
    +17.61%
    Streak
    5 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$N/A$-0.21N/ABeat-
    Mar 26
    		$0.00N/A+100.00%Beat+100.0%
    Dec 25
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    		$-0.22$-0.27+18.52%Beat+62.1%
    Jun 25
    		$-0.92$0.00N/AMiss+28.1%
    Mar 25
    		$-0.48$0.00N/ABeat-183.6%
    Dec 24
    		$-0.57$-0.68+16.18%Beat-14.0%
    Sep 24
    		$-0.58$-0.88+34.09%Beat+4.9%
    Jun 24
    		$-1.28$-0.40-220.00%Miss-103.2%
    Mar 24
    		$0.58$-0.46+226.09%Beat+200.0%
    Dec 23
    		$-0.50$-0.40-25.00%Miss-6.4%
    Sep 23
    		$-0.61$-0.90+32.22%Beat-19.6%
    Jun 23
    		$-0.63$-0.58-8.62%Miss-31.3%
    Mar 23
    		$-0.58$-0.56-3.57%Miss-31.8%
    Dec 22
    		$-0.47$-0.56+16.07%Beat-34.3%
    Sep 22
    		$-0.51$-0.51+0.00%Beat-112.5%
    Jun 22
    		$-0.48$-0.49+2.04%Beat-269.2%
    Mar 22
    		$-0.44$-0.43-2.33%Miss-388.9%
    Dec 21
    		$-0.35$-0.33-6.06%Miss-288.9%
    Sep 21
    		$-0.24$-0.16-50.00%Miss-300.0%
    Jun 21
    		$-0.13$-0.13+0.00%Beat-160.0%
    Mar 21
    		$-0.09$-0.08-12.50%Miss-80.0%
    Dec 20
    		$-0.09$-0.05-80.00%Miss+0.0%
    Sep 20
    		$-0.06$-0.07+14.29%Beat-50.0%
    Jun 20
    		$-0.05$-0.06+16.67%Beat+16.7%
    Mar 20
    		$-0.05$0.00N/ABeat+37.5%
    Dec 19
    		$-0.09$-0.14+35.71%Beat-125.0%
    Sep 19
    		$-0.04N/A+75.00%Beat+63.6%
    Jun 19
    		$-0.06$-0.12+50.00%Beat+83.3%
    Mar 19
    		$-0.08$-0.08+0.00%Beat+75.8%
    Dec 18
    		$-0.04N/A+93.44%Beat+89.2%
    Sep 18
    		$-0.11N/A+81.97%Beat+72.5%
    Jun 18
    		$-0.36$-0.65+44.62%Beat+43.8%
    Mar 18
    		$-0.33$-0.66+50.00%Beat+21.4%
    Dec 17
    		$-0.37N/AN/ABeat+11.9%
    Sep 17
    		$-0.40N/AN/ABeat+28.6%
    Jun 17
    		$-0.64$-0.47-36.17%Miss-
    Mar 17
    		$-0.42$-0.42+0.00%Beat-
    Dec 16
    		$-0.42$-0.56+25.00%Beat-
    Sep 16
    		$-0.56$-0.63+11.11%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-1.08EV/EBITDA2.08x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-85.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.08xQuick Ratio2.08x
    Trading Statistics
    Beta-0.84Avg VolumeN/A
    52-Week High$4.9852-Week Low$1.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.38
    SMA 20$2.38
    SMA 50$2.38
    SMA 200$2.21
    EMA 10$2.38
    EMA 20$2.38
    EMA 50$2.32
    EMA 200$2.24

    MACD

    Line: 0.01Signal: 0.01Hist: -0.00

    ADX

    ADX: 67.3+DI: 57.0-DI: 11.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$2.38

    Bollinger Bands

    Upper Band$2.38
    Lower Band$2.38
    %B PositionN/A
    Band Width-4.00

    RSI (14-Day)

    Overbought
    81.5

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.00(0.1%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$2.38
    OBV44.7M
    AD Line-15.3M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$2.38
    R2$2.38
    R1$2.38
    Pivot Point$2.38
    S1$2.38
    S2$2.38
    S3$2.38

    Advanced Oscillators

    TSI65.94
    Ultimate OscN/A
    KSTN/A

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.22M$0$0$0$2.35M$0
    Cost of Revenue$0$0$-18,982,000$0$0$0$20.53M$0$0$0$18.73M$0
    Gross Profit$0$0$18.98M$0$0$0$-20,530,000$0$0$0$-18,731,000$0
    Operating Expenses$9.39M$11.17M$13.55M$11.86M$45.39M$24.59M$29.49M$30.62M$61.40M$19.93M$22.79M$27.88M
    R&D$3.30M$4.54M$3.85M$3.96M$5.12M$13.67M$20.53M$17.68M$15.20M$16.23M$18.73M$23.60M
    SG&A$6.09M$6.62M$9.70M$7.91M$40.28M$10.92M$8.96M$12.95M$46.20M$3.70M$4.06M$4.28M
    Operating Income$-9,393,000$-11,168,000$-13,552,000$-11,860,000$-45,392,000$-24,586,000$-29,487,000$-30,623,000$-61,402,000$-19,934,000$-22,789,000$-27,879,000
    Interest Income$747,000$789,000$974,000$1.17M$1.21M$1.26M$0$2.62M$2.32M$0$1.58M$2.00M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-8,603,000$-10,379,000$-12,578,000$-10,693,000$-44,178,000$-23,321,000$-25,660,000$-28,005,000$6.06M$23.27M$-21,210,000$-25,874,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,603,000$-10,331,000$-12,539,000$-10,807,000$-44,224,000$-23,403,000$-27,597,000$-27,943,000$6.16M$25.04M$-20,919,000$-25,651,000
    EBITDA$-9,106,000$-10,925,000$-13,218,000$-11,729,000$-45,174,000$-24,366,000$-29,156,000$-30,364,000$4.04M$23.58M$-22,433,000$-27,487,000
    EBIT$-9,350,000$-11,168,000$-13,552,000$-11,860,000$-45,392,000$-24,586,000$-29,236,000$-30,623,000$3.74M$23.27M$-22,789,000$-27,879,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SAVA

    News

    SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

    The Klein Law Firm has announced a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA) for allegedly violating federal securities laws. The complaint claims the company made false statements regarding the efficacy and integrity of scientific data for its Alzheimer's drug, simufilam. Shareholders who suffered losses between September 14, 2020, and August 27, 2021, have until October 26, 2021, to petition for lead plaintiff status.

    TMX Newsfile•8/19/26•
    Bearish

    CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

    Bernstein Liebhard LLP is reminding investors of the October 26, 2021 deadline to file a lead plaintiff motion in a securities class action lawsuit against Cassava Sciences, Inc. The lawsuit alleges that Cassava issued false and misleading statements regarding the efficacy of its Alzheimer's drug, simufilam, and the integrity of its scientific data. These claims caused significant stock price drops following a citizen petition to the FDA and a denial from an independent company, Quanterix, regarding Cassava's data interpretation.

    TMX Newsfile•8/4/26•
    Bearish

    Cassava Sciences outlines its Alzheimer’s drug strategy as a clinical-stage biotech

    Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing novel treatments for Alzheimer's disease, with a lead drug candidate aimed at improving cognitive function. The company's strategy involves advancing this candidate through clinical trials, focusing on well-defined patient populations and neurodegenerative pathways, despite the high risks and intense competition in the Alzheimer's research field. Its stock performance is highly sensitive to clinical trial progress, regulatory updates, and market sentiment regarding the probability of successful drug approval.

    Ad-hoc-news.de•7/3/26•
    Neutral

    Cassava Sciences Inc (SAVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Cassava Sciences Inc (SAVA), highlighting its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 5.76, suggesting it is suitable for range-bound swing trading between $2.06 and $2.59. Overall, the technical indicators and moving averages for SAVA currently show a "Buy" signal.

    TradingKey•6/20/26•
    Bullish

    Cassava Sciences Inc (SAVA) Institutional Confidence

    This article from TradingKey provides an overview of institutional confidence in Cassava Sciences Inc (SAVA). It details the shares held by various institutional investors and individuals, along with the percentage change in their holdings. The data was updated on March 10, 2026, and indicates the level of institutional investment in the company.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About SAVA

    Does SAVA pay dividends?
    Cassava Sciences Inc (SAVA) has a dividend payment track record. See the SAVA dividend history page for its current payment status, yield, and streaks.
    What is SAVA's market cap?
    Cassava Sciences Inc (SAVA) has a market capitalization of $114.97M with a current stock price of $2.38.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In